Emails Promoting COVID-19 Vaccination Among Healthcare Workers
NCT ID: NCT04728594
Last Updated: 2021-07-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
9566 participants
INTERVENTIONAL
2021-01-15
2021-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Emails Promoting Mail-order Pharmacy
NCT04587063
Efficacy of Communication Modalities for Promoting Flu Shots
NCT05509270
Mail Outreach To Increase Vaccination Acceptance Through Engagement
NCT02243774
Nudging for Vaccination : Efficacity and Acceptability Among Medical Students
NCT03768596
The Influence of Doctor-patient Communication on Treatment Expectation, Placebo and Nocebo Response
NCT03949816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All emails will ask recipients if they want to receive a COVID-19 vaccination. If they click on a hyperlink indicating yes, they will be forwarded to an online registration and scheduling homepage. If they click on a hyperlink indicating no, they will be forwarded to an online questionnaire surveying people about their main reason for declining the vaccine at this time. The questionnaire will automatically present information intended to assuage the specific concern that people endorse, followed by a hyperlink to the scheduling site.
The data will be analyzed with logistic regression models with the control group as the reference group, to compare the two email conditions versus the control group. This set of analyses will only be conducted for scheduling a vaccination appointment as opposed to email engagement outcomes (e.g., number of emails opened), which will not be applicable for the control group. A second set of logistic regression models predicting scheduling a vaccination appointment and email engagement will also be run, comparing the two email conditions against each other. The data will be examined two days later (to help decide which email to send to the delayed-control group) and four days later (when the policy for employee vaccination will change, making the content of the email irrelevant).
Update: The researchers looked at 3 days of data - as the emails to the delayed contact group were only sent at that time - and 4 days of data when the policy for employee vaccinations changed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Delayed Contact
This group will not receive an email for at least two days.
No interventions assigned to this group
Social Proof
This group will receive an email that points out that vaccine availability for employees will soon be limited. It also emphasizes how many fellow health care workers have been vaccinated. Seeing the behaviors of other people might encourage recipients to copy that behavior.
Social Proof
Scarcity Message
Reframing Side Effects and Adverse Reactions
This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.
Reframing
Scarcity Message
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Social Proof
Reframing
Scarcity Message
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Geisinger Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michelle N. Meyer
Faculty Co-Director, Behavioral Insights Team
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michelle M Meyer, PhD
Role: PRINCIPAL_INVESTIGATOR
Geisinger Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geisinger
Danville, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Santos HC, Goren A, Chabris CF, Meyer MN. Effect of Targeted Behavioral Science Messages on COVID-19 Vaccination Registration Among Employees of a Large Health System: A Randomized Trial. JAMA Netw Open. 2021 Jul 1;4(7):e2118702. doi: 10.1001/jamanetworkopen.2021.18702.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-0128
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.